Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections

Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections

Purpose: Voriconazole (VOR) is combined with atorvastatin (ATO) to treat fungal infections in patients with dyslipidemia in clinical practice. However, the pharmacokinetic interactions and potential mechanisms between them are unknown. Therefore, this study aimed to investigate the pharmacokinetic i...

Full description

Bibliographic Details
Main Authors:	Tianrong Xun, Yan Rong, Bin Lv, Jinfei Tian, Qing Zhang, Xixiao Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Pharmacology
Subjects:	pharmacokinetics atorvastatin voriconazole dyslipidemia drug–drug interaction
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1165950/full

Similar Items

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
by: Jae Hoon Kim, et al.
Published: (2022-08-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Selim Ahmed, et al.
Published: (2008-04-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Salim Ahmed, et al.
Published: (2008-06-01)

Comparison between Protective Effects of Resveratrol and Atorvastatin against Atherogenic Dyslipidemia in Rats
by: Mehdi Kian, et al.
Published: (2023-12-01)

Treatment of invasive fungal infections: stability of voriconazole infusion solutions in PVC bags
by: Andréa I.H. Adams, et al.

Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia
by: Canna Jagdish Ghia, et al.
Published: (2014-03-01)

Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
by: Jaecheol Moon, et al.
Published: (2020-01-01)

EFFECTS OF ATORVASTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DYSLIPIDEMIA
by: N. M. Nikitina, et al.
Published: (2014-07-01)

EFFECTS OF ATORVASTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DYSLIPIDEMIA
by: N. M. Nikitina, et al.
Published: (2014-07-01)

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis
by: Nur Aini Hasan, et al.
Published: (2024-03-01)

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies
by: Zhao Y, et al.
Published: (2022-03-01)

An open-label prospective observational study to evaluate the efficacy and safety of alternate day versus daily dosing of atorvastatin in patients of dyslipidemia
by: Gulam Mohammad, et al.
Published: (2024-01-01)

Sensitive, High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Analysis of Atorvastatin and Its Pharmacologically Active Metabolites in Serum for Supporting Precision Pharmacotherapy
by: Gellért Balázs Karvaly, et al.
Published: (2021-03-01)

Effect of Atorvastatin in Lipid Profile Changes and Inflammation Marker TNF-alpha on Diabetes Patient with Dyslipidemia
by: Wulan Panduwi Melasari, et al.
Published: (2021-04-01)

Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
by: Ghim JL, et al.
Published: (2019-05-01)

Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial
by: Hamid Noshad, et al.
Published: (2018-12-01)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020-06-01)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
by: Gellért Balázs Karvaly, et al.
Published: (2021-10-01)

Impact of LDLR polymorphisms on lipid levels and atorvastatin’s efficacy in a northern Chinese adult Han cohort with dyslipidemia
by: Hong-Liang Zhao, et al.
Published: (2024-04-01)

Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice
by: Yan Ding, et al.
Published: (2023-11-01)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
by: Hae Won Jung, et al.
Published: (2023-09-01)

Pharmacokinetics and safety of two Voriconazole formulations after intravenous infusion in two doses in healthy Chinese subjects
by: Xin Li, et al.
Published: (2023-03-01)

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe
by: Omar ePatiño-Rodríguez, et al.
Published: (2014-11-01)

Inflammation Affects Liver Function and the Metabolism of Voriconazole to Voriconazole-N-Oxide in Adult and Elderly Patients
by: Zaiming Liang, et al.
Published: (2022-04-01)

Pharmacokinetics, safety of a single dose and multiple doses of voriconazole injection of two formulations, in Chinese healthy volunteers
by: Chunqi Huang, et al.
Published: (2022-12-01)

Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring
by: Swiss Medical Weekly
Published: (2006-11-01)

Monacolin and atorvastatin in cardiovascular prevention – an attempt at positioning
by: Marcin Barylski
Published: (2017-03-01)

Effect of Atorvastatin And Garlic on Lipid Profile in Hyperlipidemic Patients
by: Zuhair M Hussien, et al.
Published: (2019-11-01)

Effect of Atorvastatin And Garlic on Lipid Profile in Hyperlipidemic Patients
by: Zuhair M Hussien, et al.
Published: (2019-11-01)

Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
by: Ji Min Kim, et al.
Published: (2016-02-01)

Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
by: Yi-Cong Ye, et al.
Published: (2015-01-01)

Impact of extracorporeal membrane oxygenation on voriconazole plasma concentrations: A retrospective study
by: Qinghua Ye, et al.
Published: (2022-08-01)

Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid
by: Ruth Van Daele, et al.
Published: (2021-09-01)

Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases
by: Buddharat Khan-asa, et al.
Published: (2020-09-01)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
by: Josefine Schulz, et al.
Published: (2022-02-01)

Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction between Voriconazole and Tacrolimus Using Physiologically-Based Pharmacokinetic Modelling
by: Zhi-Ping Jin, et al.
Published: (2023-05-01)

To compare the safety and efficacy of intrastromal voriconazole alone and in combination with intracameral voriconazole in intractable cases of fungal keratitis
by: Monika Dahiya, et al.
Published: (2023-08-01)

The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study
by: Yi-Chang Zhao, et al.
Published: (2022-12-01)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
by: Simon Kallee, et al.
Published: (2022-09-01)

The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro
by: Xu RA, et al.
Published: (2018-11-01)